Results 201 to 210 of about 28,388 (258)

Modern antidiabetic therapy by sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors against cardiovascular diseases. [PDF]

Pharmacol Rev
Steven S, Kuntic M, Münzel T, Daiber A.
europepmc   +1 more source

Prescribing Trajectories in Type 2 Diabetes in the United States, 2019–2024

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8172-8188, September 2026.
ABSTRACT Importance Clinical guidelines for type 2 diabetes (T2D) provide population‐level recommendations, but real‐world treatment patterns evolve dynamically and vary across patients. Understanding longitudinal prescribing trajectories may reveal heterogeneity in care not captured by cross‐sectional analyses.
Tobias S. Lux, Dongkun Lee, Jeff M. Phillips, Julio C. Facelli, Daniel C. Malone, Matthew Wahl, Deepika Reddy, Farrant Sakaguchi, Ramkiran Gouripeddi, Alexander S. Millar, Matthew J. O'Brien, Joshua S. Choi, Jittrapol Sutejitsiri, Kensaku Kawamoto, Polina V. Kukhareva   +14 more
wiley   +1 more source

Association of long-term use of dipeptidyl peptidase-4 inhibitors with the risk of diabetic retinopathy in patients with diabetes mellitus: a real-world evidence study. [PDF]

Front Pharmacol
Li YC, Kuan YH, Yang Y, Gau SY, Su KY, Tsai TH, Huang KH, Lee CY.   +7 more
europepmc   +1 more source

Risk of Retinal Vein Occlusion between Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: A Retrospective Cohort Study. [PDF]

Ophthalmol Sci
Pan SY, Weng CH, Tsai SF, Sheen YJ, Lin HJ, Tien PT, Lin JF, Lin CH, Wang IJ, Chou CC.   +9 more
europepmc   +1 more source

Glucagonlike peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in ischemic strokes with diabetes 2. [PDF]

Eur J Neurol
Hastrup S, Hedegaard JN, Andersen G, Rungby J, Johnsen SP.   +4 more
europepmc   +1 more source

Exploring factors predicting the effectiveness of oral semaglutide in Japanese individuals with type 2 diabetes switching from dipeptidyl peptidase 4 inhibitors: a pilot study. [PDF]

Front Clin Diabetes Healthc
Hirotsu T, Taniguchi K, Nishimura R.
europepmc   +1 more source

Dermatological side effects of dipeptidyl Peptidase-4 inhibitors in diabetes management: a comprehensive review. [PDF]

Clin Diabetes Endocrinol
Zaresharifi S, Niroomand M, Borran S, Dadkhahfar S.   +3 more
europepmc   +1 more source

Dipeptidyl peptidase-4 inhibitor approaches.

Journal of diabetes, 2019
openaire   +1 more source

Utilization of Glucagon-Like Peptide-1 Receptor Agonist and Dipeptidyl Peptidase-4 Inhibitors at the Veterans Health Administration. [PDF]

J Pharm Technol
Krishnan A, Suryanarayanan SK, Mansi IA.
europepmc   +1 more source

Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review of Structure-Activity Relationship Studies. [PDF]

Iran J Pharm Res
Bayanati M, Ismail Mahboubi Rabbani M, Sirous Kabiri S, Mir B, Rezaee E, Tabatabai SA.   +5 more
europepmc   +1 more source